JP2017515836A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515836A5
JP2017515836A5 JP2016567364A JP2016567364A JP2017515836A5 JP 2017515836 A5 JP2017515836 A5 JP 2017515836A5 JP 2016567364 A JP2016567364 A JP 2016567364A JP 2016567364 A JP2016567364 A JP 2016567364A JP 2017515836 A5 JP2017515836 A5 JP 2017515836A5
Authority
JP
Japan
Prior art keywords
amino
methyl
phenyl
pyrazolo
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016567364A
Other languages
English (en)
Japanese (ja)
Other versions
JP6663857B2 (ja
JP2017515836A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/053174 external-priority patent/WO2015173683A1/en
Publication of JP2017515836A publication Critical patent/JP2017515836A/ja
Publication of JP2017515836A5 publication Critical patent/JP2017515836A5/ja
Application granted granted Critical
Publication of JP6663857B2 publication Critical patent/JP6663857B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016567364A 2014-05-14 2015-04-30 ピラゾロピリジンおよびピラゾロピリミジン Expired - Fee Related JP6663857B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461993138P 2014-05-14 2014-05-14
US61/993,138 2014-05-14
PCT/IB2015/053174 WO2015173683A1 (en) 2014-05-14 2015-04-30 Pyrazolopyridines and pyrazolopyrimidines

Publications (3)

Publication Number Publication Date
JP2017515836A JP2017515836A (ja) 2017-06-15
JP2017515836A5 true JP2017515836A5 (enExample) 2018-05-31
JP6663857B2 JP6663857B2 (ja) 2020-03-13

Family

ID=53264695

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567364A Expired - Fee Related JP6663857B2 (ja) 2014-05-14 2015-04-30 ピラゾロピリジンおよびピラゾロピリミジン

Country Status (29)

Country Link
US (2) US9518052B2 (enExample)
EP (1) EP3143021B1 (enExample)
JP (1) JP6663857B2 (enExample)
KR (1) KR20170002623A (enExample)
CN (1) CN106459048A (enExample)
AP (1) AP2016009562A0 (enExample)
AR (1) AR100438A1 (enExample)
AU (1) AU2015260905A1 (enExample)
CA (1) CA2948587C (enExample)
CL (1) CL2016002888A1 (enExample)
CR (1) CR20160525A (enExample)
CU (1) CU20160167A7 (enExample)
DO (1) DOP2016000298A (enExample)
EA (1) EA201650029A1 (enExample)
EC (1) ECSP16087271A (enExample)
ES (1) ES2737696T3 (enExample)
GE (1) GEP20186921B (enExample)
IL (1) IL248970A0 (enExample)
MD (1) MD20160121A2 (enExample)
MX (1) MX2016014878A (enExample)
NI (1) NI201600170A (enExample)
PE (1) PE20161475A1 (enExample)
PH (1) PH12016502228A1 (enExample)
SG (1) SG11201609139WA (enExample)
SV (1) SV2016005318A (enExample)
TN (1) TN2016000503A1 (enExample)
TW (1) TWI591067B (enExample)
UY (1) UY36121A (enExample)
WO (1) WO2015173683A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948587C (en) 2014-05-14 2018-07-17 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
TWI714528B (zh) 2014-05-14 2021-01-01 瑞士商諾華公司 甲醯胺衍生物
EP3712152B1 (en) 2015-11-03 2021-01-13 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
KR20180073687A (ko) * 2015-11-03 2018-07-02 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물
EP3371185B1 (en) 2015-11-03 2020-09-30 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
AU2018231035B2 (en) 2017-03-09 2021-09-09 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine JAK inhibitors
JP7096268B2 (ja) 2017-05-01 2022-07-05 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤化合物の結晶形態
EP3609498A1 (en) 2017-05-01 2020-02-19 Theravance Biopharma R&D IP, LLC Methods of treatment using a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
TW201920150A (zh) * 2017-08-01 2019-06-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak激酶抑制劑之吡唑并及三唑并雙環化合物
BR112020008850A2 (pt) 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
CN119080779A (zh) 2018-08-10 2024-12-06 阿克拉瑞斯治疗股份有限公司 吡咯并嘧啶itk抑制剂
CN110833555B (zh) * 2018-08-15 2023-03-24 广西梧州制药(集团)股份有限公司 吡唑并嘧啶衍生物在治疗溃疡性结肠炎的用途
AU2019335199A1 (en) 2018-09-04 2021-03-11 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
US10836763B2 (en) 2018-09-04 2020-11-17 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as JAK inhibitors
JP7324836B2 (ja) 2018-09-04 2023-08-10 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤としてのジメチルアミノアゼチジンアミド
KR20210084512A (ko) 2018-10-29 2021-07-07 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 2-아자비시클로 헥산 화합물
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
HUE067145T2 (hu) * 2019-02-25 2024-10-28 Henan Medinno Pharmaceutical Tech Co Ltd JAK inhibitor vegyület és alkalmazása
CN114075199A (zh) * 2020-08-14 2022-02-22 河南迈英诺医药科技有限公司 Jak抑制剂化合物及其用途
CN114075200A (zh) * 2020-08-14 2022-02-22 河南迈英诺医药科技有限公司 用于治疗重症肺炎的jak抑制剂化合物
AU2020265828A1 (en) 2019-05-02 2021-09-09 Aclaris Therapeutics, Inc. Substituted pyrrolopyridines as JAK inhibitors
WO2021022178A1 (en) * 2019-07-31 2021-02-04 Aclaris Therapeutics, Inc. Substituted sulfonamide pyrrolopyridines as jak inhibitors
WO2021136345A1 (zh) * 2019-12-30 2021-07-08 路良 Jak抑制剂化合物及其用途
CN113101975B (zh) * 2020-01-13 2022-04-22 万华化学集团股份有限公司 一种多膦配体催化剂体系及其在乙烯齐聚反应的应用
MX2022008627A (es) 2020-01-13 2022-11-08 Verge Analytics Inc Pirazolo-pirimidinas sustituidas y usos de las mismas.
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
CN111548269B (zh) * 2020-04-29 2023-10-27 兰州大学 一种二芳基甲烷结构化合物的制备方法
GB202010408D0 (en) * 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
WO2022053651A2 (en) 2020-09-10 2022-03-17 Precirix N.V. Antibody fragment against fap
JP2024524214A (ja) 2021-06-25 2024-07-05 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤としてのイミダゾロインダゾール化合物
CN115557947B (zh) * 2021-07-02 2024-04-02 成都百裕制药股份有限公司 吡唑并[4,3-c]吡啶衍生物及其在医药上的应用
CN113480543B (zh) * 2021-07-07 2022-05-17 无锡市第二人民医院 2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
IL318992A (en) 2022-05-02 2025-04-01 Precirix N V Cancer treatment through advance directives
WO2025217560A1 (en) * 2024-04-12 2025-10-16 Theravance Biopharma R&D Ip, Llc Triazolo indazole compounds as jak inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
EP1562898A1 (en) 2002-11-19 2005-08-17 Takeda Pharmaceutical Company Limited Indole derivatives as somatostatin agonists or antagonists
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
JP4782239B2 (ja) 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
CN101883774A (zh) * 2007-10-16 2010-11-10 惠氏有限责任公司 噻吩并嘧啶和吡唑并嘧啶化合物及其用作mtor激酶和pi3激酶抑制剂的用途
JP2011503103A (ja) * 2007-11-07 2011-01-27 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド タンパク質輸送の調節方法
US20090149458A1 (en) * 2007-11-27 2009-06-11 Wyeth PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS
CN102014914A (zh) * 2008-01-15 2011-04-13 惠氏有限责任公司 3h-[1,2,3]三唑并[4,5-d]嘧啶化合物、其作为mtor激酶和pi3激酶抑制剂的用途、以及它们的合成
JP5608099B2 (ja) * 2008-01-30 2014-10-15 ジェネンテック, インコーポレイテッド ピラゾロピリミジンpi3k阻害剤化合物および使用方法
US8163743B2 (en) * 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
WO2009153261A1 (en) * 2008-06-18 2009-12-23 Solvay Pharmaceuticals Gmbh HYDROXYPHENYL-SUBSTITUTED PYRROLO[2,3d]PYRIMIDINE DERIVATIVES, PROCESSES AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS
JPWO2010058846A1 (ja) 2008-11-21 2012-04-19 アステラス製薬株式会社 4,6−ジアミノニコチンアミド化合物
US20100317646A1 (en) * 2009-03-19 2010-12-16 Medical Research Council Technology Compounds
WO2012045195A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
CA2948587C (en) 2014-05-14 2018-07-17 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines

Similar Documents

Publication Publication Date Title
JP2017515836A5 (enExample)
JP2013523710A5 (enExample)
ES2642586T3 (es) Compuestos heterocíclicos condensados como moduladores de canales iónicos
JP4814783B2 (ja) ピラゾロピリジン誘導体
RU2018138050A (ru) Производные тиазолопиридина как агонисты gpr119
TWI756482B (zh) 治療活性化合物及其使用方法
RU2018123825A (ru) Соединения и способы для модуляции киназ, и показания для этого
JP2018534326A5 (enExample)
HRP20171913T1 (hr) Aminopirimidinilni spojevi kao inhibitori jak
JP2019504009A5 (enExample)
RU2018138047A (ru) Гетероциклические вещества - агонисты gpr119
KR20030030030A (ko) IKB-키나제 (IKK-β) 억제 활성을 갖는 피리딘 유도체
TWI455715B (zh) 4-(4-氰基-2-硫基芳基)二氫嘧啶酮類及其用途
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
JP2015514794A5 (enExample)
JP2019519484A5 (enExample)
JP2017500362A5 (enExample)
JP2013544840A5 (enExample)
JP2013502429A5 (enExample)
AU2011272800A1 (en) sGC stimulators
JP2012532931A5 (enExample)
JP2013544256A5 (enExample)
JP2014527511A5 (enExample)
JP2011518219A5 (enExample)
JP2019529443A5 (enExample)